Drug intelligence / Profile preview

doxepin + triamcinolone

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Topical

Overview

A combination therapy consisting of doxepin, a topical antihistamine, and triamcinolone, a corticosteroid. This combination is used primarily for the treatment of pruritus (itching) associated with atopic eczema and other pruritic skin conditions. Clinical studies have shown that the combination provides more effective relief of pruritus than either agent alone, with statistically significant reductions in itching severity observed within 24 hours of application. The combination also improves overall eczema disease severity.

Targets

GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on doxepin + triamcinolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxepin + triamcinolone.

Explore the full profile